The mitogen-activated protein kinase (MAPK) cascade acts regulation of cellular proliferation and differentiation of the normal hepatocyte. In the healthy liver, these pathways are as a focal point for signal transduction following activation of both G-protein-linked and tyrosine kinase growth factor tightly regulated processes by which constant liver mass and volume is maintained. 3 However, in the case of HCC, normal receptors. A common intermediate between both of these diverse receptor subtypes includes the small guanosine triphos-growth-promoting and growth-arresting components of the signal transduction circuitry become unbalanced, the net rephate (GTP)-binding protein, p21ras. Point mutations of p21ras have been identified in various tumor types and lead sult of which is uncontrolled hepatocyte growth. 4 The mitogen-activated protein kinases (MAPKs) are a to constitutive activation of this protein and subsequent activation of downstream pathways including the MAPK cascade. group of ubiquitously expressed serine/threonine kinases 5,6 and represent a point of convergence for diverse signaling Using an in vivo model of hepatocellular carcinoma (HCC), we investigated the abundance and function of individual pathways originating at the cell membrane. 6-8 Activation of the MAPK cascade occurs rapidly following ligand binding components of the MAPK cascade and the presence of specific p21ras mutations in this model. Expression of components to several distinct classes of cell surface receptors, 6,9,10 including G-protein-linked receptors [11][12][13] and tyrosine kinase of the MAPK cascade were determined in tumor and adjacent, non-neoplastic liver specimens by Western blot analysis and growth factor receptors. 14 Recent studies have identified the proto-oncogene, p21ras, as a common intermediate between functional activity confirmed by substrate phosphorylation assays. Mutations in p21ras were analyzed using an enzyme-both G-protein and tyrosine kinase-linked receptor activation and MAPK signaling. 14-16 Furthermore, point mutations linked immunosorbent assay. In tumor, extracellular regulated kinases (ERKs) ERK1, ERK2, and mitogen-activated of p21ras at either codon 12, 13, or 61 have been found to play an important role in the development of a variety of ERK-regulated kinase-1 (MEK1) were elevated by three-to fourfold as compared with adjacent nontumorigenic normal animal and human tumors. [17][18][19] The frequency of p21ras mutations in tumors varies widely between tumor types. Actiliver. In contrast, MEK2 was elevated by only 28%. Substrate vated p21ras genes are relatively rare in stomach and breast phosphorylation and detection of phosphorylated ERK1/2 tumors but are observed in 20% to 40% of lung carcinomas, proteins showed increased functional activity of these pro-30% of acute myelogenous leukemia, 40% to 50% of coloteins of the same magnitude as that observed for protein rectal tumors, and greater than 80% of pancreatic tumors. 14,20 expression. Mutations in p21ras were not detected in thisThe presen...